Bristol-Myers to acquire diabetes drug maker Amylin
Saturday, June 30, 2012 - 02:30
in Mathematics & Economics
The deal to buy the San Diego company for $5.3 billion in cash calls for Bristol-Myers to pay $31 a share, 10% more than the company's closing price Friday.Amylin Pharmaceuticals Inc., the San Diego drug maker whose treatments include the diabetes therapies Bydureon and Byetta, will be acquired by Bristol-Myers Squibb Co. for $5.3 billion in cash.